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Abstract
NK cells are multicompetent lymphocytes of the innate immune system with a central role in host
defense and immune regulation. Studies in experimental animal models of multiple sclerosis (MS)
provided evidence for both pathologic and protective effects of NK cells. Humans harbor two
functionally distinct NK-cell subsets exerting either predominantly cytotoxic (CD56dimCD161) or
immunoregulatory (CD56brightCD162) functions. We analyzed these two subsets and their functions in
the peripheral blood of untreated patients with relapsing-remitting MS compared with healthy blood
donors. While ex vivo frequencies of CD56brightCD162 and CD56dimCD161 NK cells were similar in
patients and controls, we found that cytokine-driven in vitro accumulation and IFN-g production of
CD56brightCD162 NK cells but not of their CD56dimCD161 counterparts were substantially diminished
in MS. Impaired expansion of CD56brightCD162 NK cells was cell intrinsic because the observed
effects could be reproduced with purified NK cells in an independent cohort of patients and controls.
In contrast, cytolytic NK-cell activity toward the human erythromyeloblastoid leukemia cell line K562,
the allogeneic CD41 T cell line CEM and allogeneic primary CD41 T-cell blasts was unchanged. Thus,
characteristic functions of CD56brightCD162 NK cells, namely cytokine-induced NK cell expansion and
IFN-g production, are compromised in the NK cell compartment of MS patients.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating dis-
ease of the central nervous system, which is believed to be
initiated and mediated by autoreactive T cells (1, 2). Pertur-
bations in immunomodulatory networks that include Th2
cells, regulatory T cells, NK cells and others are thought to
be in part responsible for the relapsing–remitting or chronic
progressive nature of the disease (3, 4).
NK cells are multicompetent innate lymphocytes that
originate from bone marrow precursors but can mature in
a variety of primary and secondary lymphoid tissues (5–7).
Access to these tissues and interaction with dendritic cells
(DCs) and their cytokines (i.e. IL-12 and IL-15) seems to
be required for optimal NK cell activation (8–10). The two
key effector functions of NK cells—killing and cytokine
production—are in humans mediated by two main subsets
of these innate lymphocytes that can be differentiated
from each other based on the expression of CD16 and
CD56 (10, 11). CD56dimCD16+ NK cells constitute about
90% of total blood NK cells, efficiently kill target cells and
secrete only low levels of IFN-c. In contrast,
CD56brightCD16 NK cells constitute <10% of total blood
NK cells but are enriched in secondary lymphoid tissues
(11, 12), sites of autoimmune inflammation (13) and tumors
(14). CD56brightCD16 cells produce a large amount of cyto-
kines upon stimulation but acquire cytolytic activity only after
prolonged activation (15).
In this study, we explored frequencies and effector func-
tions of CD56dimCD16+ and CD56brightCD16 blood NK cells
in untreated patients with relapsing-remitting MS compared
with healthy individuals. Our data indicate that the capability
to produce IFN-c and to proliferate following cytokine activa-
tion is impaired in NK cells of MS patients in general,
whereas cytolytic NK cell function is unchanged in MS.
Since the impaired functions are primarily mediated by
CD56brightCD16 NK cells and their expansion and IFN-c
production is mainly compromised, this NK cell subset
seems to be primarily deficient in MS patients.
Methods
Patients
Twenty treatment-naive patients with clinically definite
relapsing-remitting MS fulfilling the revised ‘McDonald’ criteria
for diagnosing MS (16, 17) and 25 healthy donors (HDs) were
enrolled in the New York cohort (Table 1). Patients were
recruited at the Corinne Goldsmith Dickinson Center for Multi-
ple Sclerosis, Mount Sinai School of Medicine (New York, NY)
and the Judith Jaffe Multiple Sclerosis Center, Weill Cornell
Medical College (New York, NY). Healthy controls were
recruited at the New York blood bank. Twelve patients with
clinically definite relapsing-remitting MS fulfilling the revised
McDonald criteria above who were treatment naive for disease
modifying drugs and were at the time of sampling at least 8
weeks after their last steroid treatment were enrolled in the
Marburg cohort (Table 2). Twelve HDs were recruited through
the Zu¨rich blood bank. The study was approved by the local
Institutional Review Boards (Institutional Review Board of the
Rockefeller University, Mount Sinai School of Medicine, Weill
Cornell Medical College and University of Marburg) and all
subjects provided informed consent.
Cell culture
PBMCs were isolated from blood samples via density centri-
fugation. PBMCs were either directly stained with monoclo-
nal antibodies or cultured for 24 and 72 h in the presence
of 100 U ml1 human recombinant (hr) IL-2 (Peprotech,
Rocky Hill, NJ, USA), 0.5 ng ml1 hrIL-12 (Peprotech) or
without addition of cytokines. For some experiments, NK
cells were isolated by negative selection using the NK cell Iso-
lation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. The purity of the
isolated NK cells was higher than 95% and contained less than
5% contaminating T cells as determined by flow cytometry.
Proliferation assay by 5,6-carboxyfluorescein diacetate
succinimidyl ester (CFSE) dilution
Purified NK cells were labeled with 5 lM CFSE in PBS for 10
min at 37C. After washing twice with PBS, cells were cul-
tured for 6 days at 37C with 0.5 ng ml1 hrIL-12 (Pepro-
tech). CFSE fluorescence was evaluated on CD3CD56+
cells by flow cytometry.
Flow cytometry
PBMC were washed in PBS and stained with the indicated
combinations of directly fluorochrome-labeled antibodies
against CD3, CD16, CD25, CD56, CD69, NKG2D, NKp44,
NKG2A, HLA-DR, CXCR1, IFN-c and a respective isotype
control (Invitrogen, Carlsbad, CA, USA) as well as IL-15 re-
ceptor alpha (IL-15Ra) and a respective isotype control
(R&D, Minneapolis, MN, USA) for 30 min at 4C. Cells
stained for IFN-c were fixed and permeabilized using the
BD Cytofix/CytopermTM Kit (BD, Franklin Lakes, NJ, USA)
according to the manufacturer’s recommendations. The cells
were washed once with PBS prior to FACS analysis. The
samples were measured on a BD LSR II or a FACS Canto II
flow cytometer. Gating and calculations for precursor fre-
quencies were performed with FlowJo software.
Cytotoxicity assay
Cytolytic NK cell activity toward susceptible target cells [the
CD4+ T cell line (CEM), which constitutively expresses the
NKG2D ligand MHC class I-related chain (MIC) A, primary
allogeneic T cell blasts and the human erythromyeloblastoid
Table 1. Patients and Controls (New York cohort)
Multiple sclerosis HD
Number 20 25
Age
(mean, range)
33.3 (18–52) na
Sex ratio
(female to male)
16:4 na
Relapsing-remitting
disease course
20 (100%) na
Disease duration
at time of samples
(mean, range in years)
5.4 (0.5–20) na
EDSS score
(mean, range in years)
1.2 (0–4) na
Total number of
attacks in first 2 years
(mean, range)
1.7 (0–5) na
Number of Gd+
lesions (mean, range)
0.7 (0–5) na
Number of T2
lesions (mean, range)
5.8 (1–17) na
Number of T1
lesions (mean, range)
0.5 (0–2) na
Treatment at time of sample 0/20 (0%) na
Table 2. Patients and controls (Marburg cohort)
Multiple sclerosis HD
Number 12 12
Age
(mean 6 SD, range)
32.8 610.2 (19–53) na
Sex ratio
(female to male)
5:1 na
Relapsing-remitting
disease course
12 (100%) na
Disease duration
at time of sampling
(mean 6 SD, range in months)
32.6 6 9.6 (24–51) na
EDSS score
(mean 6 SD, range)
1.4 6 0.6 (1.0–2.5) na
Total number of
attacks in first 2 years
(mean 6 SD, range)
2.7 6 1.0 (2–5) na
Number of Gd+ lesions
cMRI at diagnosis
(mean 6 SD, range)
0.5 6 0.9 (0–3) na
Number of T2 lesions cMRI
(mean 6 SD, range)
7.9 6 4.5 (3–17) na
Number of T1 lesions cMRI
(mean 6 SD, range)
1.4 6 1.3 (0–4) na
Treatment at time of sampling 0/12 (0%) na
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leukemia cell line K562] was quantified using a flow
cytometry-based cytotoxicity assay as previously described
(18). The fluorophore PKH-26 (Sigma) was used to label
target cells and the DNA-intercalating dye TO-PRO-3 iod-
ide (TP3; Invitrogen) to determine the viability of targeted
PHK-26+ cells upon short-term coculture with NK cells. The
extent of cytotoxicity was quantified by the relative number
of live cells, labeled with PKH-26, and dead cells, labeled
with both PKH-26 and TP3 (18, 19). Target cells were cocul-
tured with unstimulated as well as IL-2- and IL-12-
stimulated PBMCs at a ratio of 1:100 to achieve an NK cell
effector to target cell ratio of 10:1 or purified NK cells at a ef-
fector to target cell ratio of 10:1. Effector and target cells
were coincubated for 4 h to assess rapid primarily perforin-
mediated cytotoxicity of NK cells (20, 21).
Statistics
Frequencies of circulating mononuclear blood cells, of protein
expression levels as defined by mean fluorescent intensities
and of TP3+ target cells, were compared using the non-
parametric Mann–Whitney U-test and statistic significance was
judged after correction for multiple testing (Bonferroni correc-
tion). Statistical significance was indicated in the figures by
asterisks with the P-values described in the figure legends.
Results
Impaired accumulation of cytokine-activated NK cells in MS
To investigate NK cell functions in MS, we first determined
the frequencies of circulating CD3CD56dimCD16+ and
CD3CD56brightCD16 NK cells and CD3+ T cells in 20 un-
treated patients with relapsing-remitting MS compared with
25 healthy blood donors (Table 1). We found that ex vivo fre-
quencies of both NK cell subsets were unchanged in MS
(mean frequency in percent of CD3 lymphocytes 6 SEM in
HD versus MS: 20.8 6 2.6 versus 18.8 6 1.7 for
CD56dimCD16+ NK cells and 2.2 6 0.2 versus 2.1 6 0.3 for
CD56bright CD16 NK cells; Fig. 1B). Gating on total
Fig. 1. Impaired accumulation of CD3CD56brightCD16 NK cells compared with CD3CD56dimCD16+ NK cells and CD3+ Tcells in MS patients.
(A) The gating strategy leading to the composite data in (B) and (C) is shown for one representative healthy donor (HD). (B) Ex vivo frequencies
of NK cell subsets did not vary significantly between HDs and MS patients. (C) PBMCs were stimulated with cytokines IL-2 (100 U ml1) or IL-12
(0.5 ng ml1) or left unstimulated without for 72 h and percentages of CD3CD56dimCD16+ NK, CD3CD56brightCD16 NK and CD3+ Tcells were
determined. Twenty MS patients and 25 HDs are summarized. Asterisks indicate statistical significance (*P = 0.017).
NK cells in MS 141
leucocytes and relating the frequencies either to total
leucocytes or CD3 lymphocytes produced similar results
(Supplementary Figure 1 is available at International
Immunology Online). In order to study the ability of patients’
NK cells to expand, we next exposed PBMCs to NK cell-
activating cytokines, i.e. IL-2 (100 U ml1) as classical NK
cell mitogen and IL-12 (0.5 ng ml1) as NK cell-activating
monokine, and determined NK cell and T-cell frequencies
after 72 h of in vitro culture. Limiting amounts of IL-12 were
chosen to mimic DC-induced NK cell accumulation and
IFN-c secretion (8, 10). CD16 was not down-regulated
significantly in sorted NK cell subsets with and without
cytokines over 72 h under our experimental conditions (Sup-
plementary Figure 2 is available at International Immunology
Online). As demonstrated before (10), CD56brightCD16 NK
cells preferentially expand in response to IL-12 treatment.
Under these conditions, we found that NK cells from MS
patients differed from those derived from healthy controls
in their capacity to accumulate in response to activating
cytokines (Fig. 1). In accordance with the NK cell subset
preference of IL-12 stimulation, accumulation of
CD3CD56brightCD16 NK cells from MS patients was
impaired in response to this cytokine (34% reduction com-
pared with mean frequencies in HD; P = 0.003). Further-
more, accumulation of IL-2-stimulated CD56brightCD16 NK
cells (P = 0.04) and IL-12-stimulated CD56dimCD16+ NK
cells (P = 0.03) tended to be lower in MS patients. However,
only the aforementioned differences did reach statistical sig-
nificance following Bonferroni correction (alpha = 0.017),
suggesting a predominant impairment of IL-12-mediated
CD56brightCD16 NK cell accumulation in MS. Frequencies
of CD3+ T cells from patients and controls were similar in cul-
tures treated with and without cytokines and cultures from
MS patients did not differ significantly from those derived
from controls in total numbers of live cells as determined by
trypan-blue staining after 72 h of culture (data not shown).
These data indicate an impairment of CD56brightCD16 NK
cells from MS patients to accumulate in response to the NK
cell activating monokine IL-12.
Phenotype of blood NK cells in MS indicates increased in vivo
activation
We next determined the expression profile of inhibitory
(NKG2A) and stimulatory NK cell receptors (NKG2D and
NKp44) as well as surface markers indicative of activation
(CD25, CD69 and HLA-DR) and homing to inflammatory
sites (CXCR1) on unstimulated and cytokine-treated NK cells
(Bonferroni correction, alpha = 0.007). Frequencies of both
CD56brightCD16 and CD56dimCD16+ NK cells expressing
HLA-DR (P = 0.008 and P = 0.02, respectively) and CD69
(P = 0.12 and P = 0.03, respectively) tended to be in-
creased in untreated cultures from patients with MS (Fig. 2).
Similar tendencies could be observed following IL-2 stimula-
tion for CD56bright and CD56dim NK cells expressing HLA-
DR (P = 0.01 and P = 0.01, respectively) and CD69 (P =
0.82 and P = 0.001, respectively). IL-12 stimulation led to
an expansion of HLA-DR+ and CD69+ NK cells in healthy
controls but showed only minimal effects in MS patients,
resulting in a loss of differences between both groups.
Following correction for multiple testing, we found that only
CD69-expressing CD56dimCD16+ NK cells were moderately
increased in frequency in IL-2-treated cultures from
MS patients. Frequencies of NK cells expressing NKG2A,
NKG2D, NKp44, CD25 and CXCR1 as well as of T cells
expressing these markers including HLA-DR and CD69
were similar in patients and controls in all conditions tested
(data not shown). Thus, impaired accumulation of
CD56brightCD16 NK cells is associated with mode-
rately higher frequencies of CD69+CD56dimCD16+ NK cells,
suggesting slightly increased in vivo activation of these cells
in MS.
Impaired IFN-c production by CD56brightCD16 NK cells in
MS
To further investigate NK cell function in patients with MS, we
determined IFN-c production by intracellular cytokine stain-
ing after short-term restimulation of NK cells and T cells in
vitro. As expected, significant IFN-c production was ob-
served only in IL-12-activated CD56brightCD16 NK cells
and IL-12 stimulation elicited higher frequencies of IFN-c
-positive CD56brightCD16 NK cells in than IL-2 stimulation
(Fig. 3). IFN-c production by CD56brightCD16 NK cells was
severely diminished in MS patients (52% decrease from HD
to MS upon IL-12 stimulation, P = 0.002). This difference
remained statistically significant following Bonferroni correc-
tion (alpha = 0.017). Both CD56dimCD16+ NK cells, as well
as T cells, produced only low to undetectable amount of
IFN-c in response to the used stimuli (Fig. 3). These data in-
dicate that CD56brightCD16 NK cells of MS patients are not
only impaired in their ability to accumulate but also produce
less IFN-c than their counterparts from HDs after stimulation
with IL-12.
IL-15 receptor alpha expression on NK cells and T cells in MS
We have recently shown that IL-15 receptor alpha (IL-15Ra)
accumulates at the synapse between human DCs and NK
cells and contributes to NK cell survival (22). Lack of IL-
15Ra surface expression on NK cells and T cells has been
documented in individuals with a history of infectious mono-
nucleosis (IM) (23), a syndrome associated with a moderately
increased risk to develop MS (24, 25). We therefore investi-
gated whether poor NK cell expansions would be associ-
ated with a lack of or impaired expression of IL-15Ra in MS
patients. We determined expression levels of IL-15Ra in
CD56brightCD16 NK cells, CD56dimCD16+ NK cells and
CD3+ T cells as well as frequencies of IL-15Ra-expressing
lymphocytes. Membrane-bound IL-15Ra could be detected
in both CD56brightCD16 and CD56dimCD16+ NK cell sub-
sets as well as in T cells (Supplementary Figure 3A is avail-
able at International Immunology Online). Expression levels
of membrane-bound as well as of total IL-15Ra proteins
were similar in MS patients and controls in any cell compart-
ment studied (Supplementary Figure 3B is available at Inter-
national Immunology Online). Furthermore, the frequency of
IL-15Ra-expressing cells was similar in patients and in con-
trols (IL-15Ra surface expression: mean frequency in per-
cent of CD3 lymphocytes 6 SEM in HD versus MS: 1.5 6
0.2 versus 2.1 6 0.4 for CD56dim CD16+ NK cells and
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0.9 6 0.1 versus 1.3 6 0.2 for CD56bright CD16 NK cells
and 3.1 6 0.5 versus 2.5 6 0.4 for T cells; total IL-15Ra ex-
pression: 8.8 6 1.4 versus 12.1 6 2.3 for CD56dim CD16+
NK cells and 6.5 6 1.0 versus 4.4 6 0.6 for CD56bright
CD16 NK cells and 19.4 6 2.0 versus 10.1 6 1.6 for
T cells). We conclude that impaired NK cell accumulation
does not result from reduced expression or absence of the
high-affinity IL-15Ra chain in MS.
Cytolytic NK cell function is unchanged in MS
NK cells have been proposed to mediate their immunoregu-
latory functions in MS and various experimental autoimmune
encephalomyelitis (EAE) models via killing of encephalito-
genic T cells (26–28). Previous studies have shown that hu-
man antigen-activated T lymphocytes express cell-surface
NKG2D ligands via an ATM/ATR-dependent mechanism
and become susceptible to autologous NK-cell lysis (29).
We therefore analyzed the cytolytic activity of NK cells in
patients with MS compared with healthy blood donors us-
ing a CD4+ T cell line (CEM), which constitutively expresses
the NKG2D ligand MHC class I-related chain (MIC) A, pri-
mary allogeneic T cell blasts and the human erythromyelo-
blastoid leukemia cell line K562 as target cells. The
fluorophore PKH-26 was used to label target cells and
the DNA-intercalating dye TO-PRO-3 iodide (TP3) to deter-
mine the viability of targeted PHK-26+ T cells upon short-
term coculture with NK cells. The extent of cytotoxicity was
quantified by the relative number of live T cells labeled with
PKH-26 and dead permeabilized cells labeled with both
PKH-26 and TP3 (18, 19) (Fig. 4). Effector and target cells
were coincubated for 4 h to assess rapid primarily
perforin-mediated cytotoxicity of NK cells (20, 21). The
Fig. 2. Frequencies of HLA-DR+ and CD69+ NK cells in MS. PBMCs were stimulated with cytokines (IL-2 or IL-12) or left unstimulated without for
72 h. HLA-DR and CD69 surface expression was analyzed by flow cytometry for CD56brightCD16 (left two columns) and CD56dimCD16+ NK cells
(right two columns). Twenty MS patients and 25 healthy donors (HD) are summarized. Asterisks indicate statistical significance (*P = 0.007).
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frequency of CEM CD4+ T cells, primary T-cell blasts and
the K562 cell line undergoing spontaneous cell lysis was
consistently lower than 10% (Figs 5 and 6). Coculture
with non-stimulated and activated effector cells substan-
tially increased target cells lysis. The extent of NK cell-
mediated cytotoxicity varied among both patients and
controls. While the cytotoxic activity of NK cells tended to
be higher in some MS patients for CEM CD4+ T cells and
primary T-cell blasts and lower for the K562 cell line,
the overall difference was not statistically significant for any
of the conditions tested (Figs 5 and 6). We additionally
determined spontaneous cytotoxicity toward the human
erythromyeloblastoid leukemia cell line K562 by sorted NK
cells and found no differences between patients and con-
trols (mean 6 SEM of TO-PRO+/PKH+ cells in HD versus
MS: 55.1 6 8.1 versus 40.7 6 6.2; Fig. 6). These data do
not argue for an impaired cytolytic potential of NK cells
in MS and indicate that NK cell effector functions attributed
to distinct NK cell subsets are differentially affected in
patients with MS.
Impaired cytokine induced proliferation of NK cells from MS
patients
In order to confirm our data of impaired expansion of
CD56brightCD16 NK cells, we recruited a second cohort of
MS patients and healthy controls from Marburg, Germany
(Table 2). Similar to our first patients’ cohort, ex vivo frequen-
cies of CD56brightCD16 and CD56dimCD16+ NK cells were
unchanged in comparison with HDs (Fig. 7A). However, after
6 days of IL-12 stimulation in vitro, CD56brightCD16 NK cells
accumulated less in MS patients than in healthy controls,
while CD56dimCD16+ remained at similar frequencies
(Fig. 7B). In addition, proliferation of purified total NK cells
and the NK cell subsets as assessed by CFSE dilution after
IL-12 stimulation in vitro was compromised, even so the
decrease in CD56brightCD16 NK cell proliferation did not
reach statistical significance (Fig. 7C). Thus, NK cell
proliferation and CD56brightCD16 NK cell accumulation are
cell intrinsically deficient in MS patients. These data confirm
in an independent MS cohort decreased function of
CD56brightCD16 NK cells in MS patients.
Fig. 3. Reduced IFN-c production in IL-12-stimulated CD56brightCD16 NK cells of MS patients. PBMCs were stimulated with cytokines (IL-2 or
IL-12) or left unstimulated without for 24 h. Percentages of IFN-c-positive CD56brightCD16, CD56dimCD16+ and total NK cells after stimulation
with the indicated cytokines were determined. (A) One representative MS patient is shown. (B) Twenty MS patients and 25 healthy donors (HD)
are summarized. Asterisks indicate statistical significance (**P = 0.001, *P = 0.017).
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Discussion
Our study provides evidence for a functional deficiency of
CD56brightCD16 NK cells in untreated patients with MS. In
vitro activation of NK cells from MS patients, even with limit-
ing concentrations of IL-12, resulted in impaired accumula-
tion of CD56brightCD16 NK cells. Furthermore,
CD56brightCD16 NK cells from MS patients produced re-
duced amounts of IFN-c following IL-12 stimulation, whereas
cytolytic NK cell functions toward the classical target cell
line K562, allogeneic CD4+ T cells, constitutively expressing
NKG2D ligands, and allogeneic primary CD4+ T cell blasts
were unchanged in MS. These data suggest a selective im-
pairment of CD56brightCD16 NK cells and with IFN-c pro-
duction as well as proliferation compromised hallmark
effector functions of this NK cell subset in MS patients.
Studies in animals models of MS suggested that NK cells
limit autoimmune tissue inflammation via killing of encephali-
togenic effector T cells since antibody-mediated NK cell de-
pletion exacerbated EAE pathology in different rodent
strains associated with enhanced T-cell responses to the
Fig. 4. NK cell cytotoxicity against T cell blasts. NK cells kill the CD4+ T-cell lymphoblast-like cell line CEM, constitutively expressing NKG2D
ligands (A) and allogeneic primary CD4+ Tcell blasts (B). PBMCs were stimulated with IL-2 or IL-12 for 72 h. Primary CD4+ Tcells were stimulated
with PHA (2.5 ng ml1) for 48 h. All experiments were performed at a NK cell:target cell ratio of 10:1. NK cell cytotoxicity was assessed as
percentage of TO-PRO-3-positive (membrane integrity deficient) cells among the PKH-26-labeled target cells after 4 h coculture with the
indicated NK cell lines. Activated NK cell lines from 1 of 25 healthy blood donors are shown.
Fig. 5. MS patients do not differ from healthy donors (HDs) in their NK cell cytotoxicity against T cell blasts. Cytotoxic activity of unstimulated
without and cytokine (IL-2 or IL-12)-activated NK cells toward (A) a CD4+ Tcell lymphoblast-like cell line constitutively expressing NKG2D ligands
(CEM) and (B) PHA-activated T cell blasts is unchanged in MS. NK cell cytotoxicity was assessed as percentage of TO-PRO-3-positive
(membrane integrity deficient) cells among the PKH-26-labeled target cells after 4 h coculture with the indicated NK cell lines. Twenty MS
patients and 25 HDs are summarized.
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immunizing neuroantigen in vitro (26, 30). In addition, innate
lymphocytes, via IFN-c production, are reported to inhibit
the development of pathogenic Th1 and Th17 effector
responses in experimental models of autoimmune diseases
(31, 32). Several studies reported that individuals with auto-
immune syndromes such as MS and systemic lupus erythe-
matodes have fewer blood NK cells than healthy subjects
and NK cells isolated from patients with MS were found not
only to be decreased in frequency but also to be impaired
in effector function (33–37). On the contrary, other studies
found no differences in NK cell frequencies and functions
between patients with MS and other autoimmune diseases
compared with healthy controls (38–41). These seemingly
contradictory findings are difficult to interpret since all the
aforementioned studies differed widely in their criteria used
to classify NK cells. Some of the older reports did not distin-
guish between NK cells and NKT cells and none of the
above studies differentiated between CD56brightCD16 and
CD56dimCD16+ NK cells. Moreover, the assays and proto-
cols used to study NK cell frequencies and functions, as well
as the patient populations studied, varied significantly (42).
In our study, differences between MS patients and controls
were confined to the CD56brightCD16 subset and undetect-
able unless NK cells were exposed to activating cytokines
in vitro.
Among the soluble factors, IL-12 is thought to be the most
pivotal signal-enhancing factor for NK cell effector functions
in humans and in mice (8, 10,43–45). Yet, a recent study
suggests that IL-15 acts as an even earlier and more crucial
regulator of NK cell differentiation and function, at least in
mice (9). After in vivo stimulation with TLR ligands or bacte-
rial and viral infection, it was shown that myeloid CD11chigh
DCs need to prime NK cells via presentation of IL-15 to pro-
duce IFN-c and become cytotoxic against a MHC class I
low cell line-expressing NKG2D ligands. In humans, we have
recently shown that IL-15Ra accumulates at the synapse be-
tween DCs and NK cells and contributes to NK cell survival
(22). Although individuals with a history of IM, a MS-
predisposing syndrome (24, 25), are reported to lack ex-
pression of IL-15Ra on NK cells (23), we could exclude
that the poor expansion and cytokine production of
CD56brightCD16 NK cells are due to an impaired expres-
sion of the high-affinity IL-15 receptor. Instead, persistent
NK cell activation, as can be envisioned during relapsing-
remitting MS, could exhaust the NK cell compartment, differ-
entiating more CD56brightCD16 NK cells into CD56dimCD16+
NK cells. Both IL-12 and IL-15, monokines produced during
immune responses as well as the lymphokine IL-2 can differ-
entiate immunoregulatory into cytotoxic NK cells in vitro and
in vivo (7, 46, 47). Consistent with this hypothesis, we found
decreased immunoregulatory NK cell functions (accumula-
tion and cytokine production by CD56brightCD16 NK cells),
Fig. 6. NK cell cytotoxicity against erythroleukemic cells. Cytotoxic
activity of unstimulated sorted NK cells toward the standard target cell
line K562 is unchanged in MS. NK cell cytotoxicity was assessed as
percentage of TO-PRO-3-positive (membrane integrity deficient) cells
among the PKH-26-labeled target cells after 4 h coculture with the
indicated NK cell line. Fourteen MS patients and 14 healthy donors
(HDs) are summarized.
Fig. 7. Accumulation and proliferation of NK cells are impaired in an
independent cohort of MS patients and are independent from T cells.
The cohort of MS patients from Marburg, Germany (see Table 2),
was analyzed in comparison with HDs in the NK cell subset
frequencies ex vivo (A). After 6 days incubation with IL-12, the
accumulation of CD56brightCD16 NK cells was quantified (B). The
proliferation of purified total NK cells and the indicated NK cell
subsets of MS patients were analyzed in comparison with HDs by
CFSE dilution (C). Representative contour blots of one HD and one
MS patient are shown. Data of 12 MS patients and 12 HDs measured
in triplicates are summarized. Asterisks indicate statistical signifi-
cance (***P = 0.0004, **P =0.026).
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but normal NK cell cytotoxicity, mainly mediated by
CD56dimCD16+ NK cells.
It remains to be determined whether the deficiency in
CD56brightCD16 NK cell function contributes to the immuno-
pathology of MS or reflects an epiphenomenon without any
consequence for disease development and progression.
However, the fact that CD56brightCD16 NK cells expand
during effective immunotherapies (27, 48, 49) and correlate
with the inhibition of contrast-enhancing lesions on brain
magnetic resonance imaging (MRI) during immunotherapy
with a monoclonal antibody targeting the IL-2R alpha chain,
i.e. daclizumab (27), suggests that these innate lymphocytes
exert beneficial immunoregulatory functions in MS.
In summary, we have demonstrated that untreated patients
with MS show impaired regulatory NK cell responses, which
could be attributed to the abundant NK cells in secondary
lymphoid tissues, namely CD56brightCD16 NK cells. The
functional deficiency in MS is restricted to IFN-c production
upon immune activation and does not affect the cytolytic po-
tential of NK cells. These data reinforce the notion that NK
cells, originally named after their ability to mediate spontane-
ous cytotoxicity toward certain tumor cell lines, regulate au-
toimmune responses and suggest that CD56brightCD16 NK
cells should be further explored for their immunotherapeutic
potential in MS.
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Supplementary data are available at International Immunol-
ogy Online.
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